LeonaBio

LeonaBio Net Debt

The Net Debt of LeonaBio (LONA) as of Oct 16, 2026 is -87.53 M USD. In the previous year, Net Debt was -50.06 M USD — a change of 74.85% (lower).

Net Debt

-87.53 MUSD

YoY

74.85%

Last updated:

Net Debt of LeonaBio is 2025 -87.53 M USD. Net Debt of LeonaBio was 2024 -50.06 M USD. It decreases by 74.85% lower compared to the previous year.

The LeonaBio Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-4.10 M USD
Jan 1, 2019
-503,000.00 USD
Jan 1, 2020
-183.68 M USD
Jan 1, 2021
-251.84 M USD
Jan 1, 2022
-198.43 M USD
Jan 1, 2023
-145.83 M USD
Jan 1, 2024
-50.06 M USD
Jan 1, 2025
-87.53 M USD
The LeonaBio Net Debt history
YEARNet DebtYoY
-87.53 MUSD+74.85%
-50.06 MUSD-65.67%
-145.83 MUSD-26.51%
-198.43 MUSD-21.21%
-251.84 MUSD+37.11%
-183.68 MUSD+36,417.30%
-503,000.00USD-87.72%
-4.10 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? LeonaBio Inc, trading under the ticker LONA with ISIN US04746L2034, is a U.S.-based company headquartered in Bothell, Washington. Operating within the Health Care sector, specifically in the Pharmaceuticals industry, the company has a workforce of 20 employees. LeonaBio Inc. completed its initial public offering (IPO) on September 18, 2020. The company's website is https://www.athira.com/. It is important to note that the provided source description refers to Athira Pharma, Inc., which appears to be a different entity from LeonaBio Inc. The source description mentions a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, with a pipeline built from an ATH platform. However, these details are not confirmed as part of LeonaBio Inc. and should not be attributed to it. The company's actual business focus, product pipeline, or technological platforms are not specified in the provided information. LeonaBio Inc. is a publicly traded company with a small team, operating in the pharmaceutical space, but specific details about its products, research, or development activities are not included in the facts provided. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

Net Debt of LeonaBio is -87.53 M USD in 2025.

Net Debt of LeonaBio changed from -50.06 M USD to -87.53 M USD, representing a 74.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt LeonaBio since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's LeonaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — LeonaBio

All Key Metrics — LeonaBio